Kidney cancer: Systemic therapy - Differentiating the achievable from the achieved

Reza Mehrazin; Matthew D. Galsky

doi:10.1038/nrurol.2014.358

Kidney cancer: Systemic therapy - Differentiating the achievable from the achieved

Reza Mehrazin, Matthew D. Galsky

Research output: Contribution to journal › Short survey › peer-review

3 Scopus citations

Abstract

Over the past few years the management of patients with metastatic renal cell carcinoma has changed substantially. Although the development of targeted therapies has improved the prognosis of many patients with renal cell carcinoma, a large subset of patients who might benefit from targeted therapies do not receive such treatments.

Original language	English
Pages (from-to)	128-129
Number of pages	2
Journal	Nature Reviews Urology
Volume	12
Issue number	3
DOIs	https://doi.org/10.1038/nrurol.2014.358
State	Published - 11 Mar 2015

Access to Document

10.1038/nrurol.2014.358

Cite this

@article{4b6b99712264464e99f9790d9765cfc7,

title = "Kidney cancer: Systemic therapy - Differentiating the achievable from the achieved",

abstract = "Over the past few years the management of patients with metastatic renal cell carcinoma has changed substantially. Although the development of targeted therapies has improved the prognosis of many patients with renal cell carcinoma, a large subset of patients who might benefit from targeted therapies do not receive such treatments.",

author = "Reza Mehrazin and Galsky, {Matthew D.}",

year = "2015",

month = mar,

day = "11",

doi = "10.1038/nrurol.2014.358",

language = "English",

volume = "12",

pages = "128--129",

journal = "Nature Reviews Urology",

issn = "1759-4812",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - Kidney cancer

T2 - Systemic therapy - Differentiating the achievable from the achieved

AU - Mehrazin, Reza

AU - Galsky, Matthew D.

PY - 2015/3/11

Y1 - 2015/3/11

N2 - Over the past few years the management of patients with metastatic renal cell carcinoma has changed substantially. Although the development of targeted therapies has improved the prognosis of many patients with renal cell carcinoma, a large subset of patients who might benefit from targeted therapies do not receive such treatments.

AB - Over the past few years the management of patients with metastatic renal cell carcinoma has changed substantially. Although the development of targeted therapies has improved the prognosis of many patients with renal cell carcinoma, a large subset of patients who might benefit from targeted therapies do not receive such treatments.

UR - http://www.scopus.com/inward/record.url?scp=84924631018&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2014.358

DO - 10.1038/nrurol.2014.358

M3 - Short survey

C2 - 25600095

AN - SCOPUS:84924631018

SN - 1759-4812

VL - 12

SP - 128

EP - 129

JO - Nature Reviews Urology

JF - Nature Reviews Urology

IS - 3

ER -

Kidney cancer: Systemic therapy - Differentiating the achievable from the achieved

Abstract

Access to Document

Fingerprint

Cite this